These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 32636051)

  • 1. [Anti-PD1 immunotherapy followed by tuberculosis infection or reactivation].
    Viatgé T; Mazières J; Zahi S; Fajadet P; Pétureau F
    Rev Mal Respir; 2020 Sep; 37(7):595-601. PubMed ID: 32636051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dermatomyositis associated with nivolumab therapy for melanoma: a case report and review of the literature.
    Messer A; Drozd B; Glitza IC; Lu H; Patel AB
    Dermatol Online J; 2020 Aug; 26(8):. PubMed ID: 32941716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Third degree atrio-ventricular blockade during a myocarditis occurring under anti-PD1 : Case report and literature review].
    Prevel R; Colin G; Calès V; Renault PA; Mazieres J
    Rev Med Interne; 2020 Apr; 41(4):284-288. PubMed ID: 31983550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe pulmonary infections complicating nivolumab treatment for lung cancer: a report of two cases.
    Inthasot V; Bruyneel M; Muylle I; Ninane V
    Acta Clin Belg; 2020 Aug; 75(4):308-310. PubMed ID: 31179880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Difficulties in differentiating between checkpoint inhibitor pneumonitis and lung metastasis in a patient with melanoma.
    Safa H; Bhosale P; Weissferdt A; Oliva ICG
    Immunotherapy; 2020 Apr; 12(5):293-298. PubMed ID: 32295435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
    Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
    Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Can nivolumab be used safely in idiopathic pulmonary fibrosis?].
    Duchemann B; Didier M; Pailler MC; Brillet PY; Kambouchner M; Uzunhan Y; Freynet O; Chouahnia K; Zelek L; Nunes H
    Rev Mal Respir; 2019 Feb; 36(2):209-213. PubMed ID: 30686563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of High Dose Hypofractionated Radiotherapy with Anti-PD1 Single Dose Immunotherapy Leads to a Th1 Immune Activation Resulting in a Complete Clinical Response in a Melanoma Patient.
    Milhem C; Moralès O; Ingelaere C; Pasquier D; Mordon S; Mortier L; Mirabel X; Delhem N
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32942768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should immune checkpoint inhibitors be contraindicated in lung cancer patients with latent tuberculosis?
    Haddad FG; Kattan C; Kattan J
    Immunotherapy; 2020 Aug; 12(11):759-762. PubMed ID: 32517560
    [No Abstract]   [Full Text] [Related]  

  • 10. Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series.
    Naqash AR; File DM; Ziemer CM; Whang YE; Landman P; Googe PB; Collichio FA
    J Immunother Cancer; 2019 Jan; 7(1):4. PubMed ID: 30621779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma.
    Indini A; Di Guardo L; Cimminiello C; Prisciandaro M; Randon G; De Braud F; Del Vecchio M
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):511-521. PubMed ID: 30539281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Squamous cell carcinoma or squamous proliferation associated with nivolumab treatment for metastatic melanoma.
    Vu M; Chapman S; Lenz B; Wohltmann W
    Dermatol Online J; 2022 Jun; 28(3):. PubMed ID: 36259805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Not Available].
    Mateus C; Libenciuc C; Robert C
    Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of corticosteroid use during anti-PD1 treatment.
    Pan EY; Merl MY; Lin K
    J Oncol Pharm Pract; 2020 Jun; 26(4):814-822. PubMed ID: 31495293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteonecrosis of the jaw induced by treatment with anti-PD-1 immunotherapy: a case report.
    Pundole X; Jones AL; Tetzlaff MT; Williams MD; Murphy WA; Otun A; Goepfert RP; Davies MA
    Immunotherapy; 2020 Dec; 12(17):1213-1219. PubMed ID: 32900256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
    Bozorgmehr F; Hommertgen A; Krisam J; Lasitschka F; Kuon J; Maenz M; Huber PE; König L; Kieser M; Debus J; Thomas M; Rieken S
    BMC Cancer; 2019 Nov; 19(1):1074. PubMed ID: 31703637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tuberculosis infection following immune checkpoint inhibitor treatment for advanced cancer: a case report and literature review.
    Lin C; Xu G; Gao S; Feng T; Li S
    Front Immunol; 2023; 14():1162190. PubMed ID: 37304292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
    Masuda K; Shoji H; Nagashima K; Yamamoto S; Ishikawa M; Imazeki H; Aoki M; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Boku N
    BMC Cancer; 2019 Oct; 19(1):974. PubMed ID: 31638948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversible primary adrenal insufficiency related to anti-programmed cell-death 1 protein active immunotherapy: Insight into an unforeseen outcome of a rare immune-related adverse event.
    Deligiorgi MV; Trafalis DT
    Int Immunopharmacol; 2020 Dec; 89(Pt B):107050. PubMed ID: 33069924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
    Afzal MZ; Mabaera R; Shirai K
    J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.